Business · 29/01/1997Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for DIFFERIN Solution Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of DIFFERIN Solution, a human drug product, as required by law following a submission to the Commissioner of Patents and Trademarks, Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →